CD19 CAR-γδ T cell therapy for relapsed/refractory B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental cell therapy using your own immune cells (gamma-delta T cells) that are engineered to find and kill cancer cells that carry a protein called CD19. It is for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 14 years.
- You have B-cell acute lymphoblastic leukemia that is relapsed or refractory (did not respond to treatment or came back).
- Your cancer cells must test positive for CD19 (a protein on the surface).
- You have a life expectancy of more than 3 months and a performance status (ECOG) of 0-2 (you can do most daily activities).
- Your heart, kidney, and liver function must be within acceptable limits as checked by tests.
- You must agree to use effective birth control during treatment and for 1 year after (if you are of childbearing age).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
Hear when a new Relapsed/Refractory CD19-positive B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.